Cellular Dynamics International (CDI) Launches Opsis Therapeutics to Develop Cell Therapies for Retinal Diseases
MADISON, WIS, September 28, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company and the leading developer and manufacturer of induced pluripotent stem cell (iPSC) products, today announced a new venture, named Opsis Therapeutics. Formed on July 31, Opsis Therapeutics is focused on discovering and developing novel medicines to treat patients suffering from retinal diseases. [Read more…]
FDA Approves the Cleveland Cord Blood Center’s CLEVECORD™ for Stem Cell Transplants
CLEVELAND, Sept. 12, 2016 /PRNewswire-USNewswire/ — The U.S. Food and Drug Administration (FDA) has issued a biologics license to the Cleveland Cord Blood Center (CCBC) for CLEVECORD™, a stem cell product (HPC, Cord Blood) derived from umbilical cord blood. Under this license, CCBC is authorized to manufacture CLEVECORD, for use in unrelated hematopoietic cell transplantation in patients with disorders affecting the hematopoietic system such as leukemia, lymphoma and immune system disorders.
“Obtaining FDA licensure for CLEVECORD is reflective of the Cleveland Cord Blood Center’s dedication to meeting the highest quality standards in the industry for distribution of our cord blood products to transplant centers throughout the U.S. and around the world,” said Wouter Van’t Hof, the CCBC’s Cord Blood Bank Director. “The ability to meet such standards is indicative of the commitment of our organization to providing high quality transplant options to patient populations that are underserved in hematopoietic transplantation. It also stages the pursuit of new life-saving and life-enhancing research and product development opportunities.”
Top 10 iPSC Talks from Axiogenesis’ American User Symposium
Axiogenesis hosted an American user symposium titled, “iPSC Derived Cells & Assays Come of Age.” Held in Boston, Massachusetts (June 13, 2016), the symposium explored how experts in the pharmaceutical industry and academia use Axiogenesis’ cells and assays within drug discovery, safety/toxicology screening, and bioengineering applications.
It also presented current approaches to establish and define standards for these cellular models. Widely attended by representatives from the pharmaceutical sector, symposium attendees had the valuable opportunity to view case studies of iPSC-derived cells utilized in drug development decision-making and biomedical research.
To capture highlights from the event and facilitate thought-provoking conversation, below is a list of the top 10 talks from the recent Axiogenesis’ iPSC user symposium. [Read more…]
Abeona Therapeutics Announces Licensing of the AIM ™ Next Generation AAV Gene Therapy Vector Platform from The University of North Carolina at Chapel Hill
- AIM™ vector system is a novel AAV-based vector technology platform that may target CNS and other tissues with increased efficiency and tissue specificity
- Exclusive worldwide license adds ABO-202, an AAV gene therapy product, for the treatment of CLN1 patients with infantile neuronal ceroid lipofuscinosis (INCL, infantile Batten disease) to Abeona’s Batten pipeline; clinical trials anticipated 2017
- « Previous Page
- 1
- …
- 123
- 124
- 125
- 126
- 127
- …
- 194
- Next Page »